Please assess the completion status of the following clinical trial:

Trial Title: Study of Oral Topotecan With Bevacizumab for Recurrent Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed diagnosis of SCLC.~* First recurrence of SCLC after therapy with one prior chemotherapy regimen at initial diagnosis.~* Relapsed SCLC of any duration (both sensitive and resistant relapse).~* ECOG performance status of \</= 2.~* Adequate bone marrow reserve, hepatic, renal, and cardiovascular function.~* No prior therapy with bevacizumab or any other VEGF inhibitor or topotecan~Exclusion Criteria:~* Uncontrolled emesis, regardless of etiology.~* Active uncontrolled infection.~* GI conditions or drugs that could impact absorption of oral topotecan.~* Known hypersensitivity to any component of topotecan capsule or compounds chemically related to topotecan.~* Uncontrolled hypertension with BP\>150/100.~* Prior h/o hypertensive crisis or encephalopathy.~* NYHA Grade II or greater congestive heart failure.~* H/O myocardial infarction within 6 months.~* H/O stroke or TIA within 6 months.~* H/O thrombotic or hemorrhagic disorders.~* Clinically significant vascular disease (e.g., aortic aneurysm requiring surgical repair or recent peripheral arterial thrombosis) within 6 months.~* Major surgical procedure, open biopsy, or significant traumatic injury within 28 days.~* Anticipation of need for major surgical procedure during the study.~* Minor surgical procedures within 7 days prior to treatment start (placement of vascular access devices is permitted).~* H/O abdominal fistula, GI perforation, or intra-abdominal abscess within prior 6 months. Serious, non-healing wound, active ulcer, or untreated bone fracture. - H/O hemoptysis within prior 1 month.~* Concurrent radiotherapy.~* H/O whole lung radiation within 90 days prior to start of treatment.~* Presence or h/o central nervous system or brain metastases.~* H/o another malignancy other than SCLC.~* Concurrent chemotherapy, immunotherapy, or investigational therapy for the treatment of small cell lung cancer.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Open label, Single arm (Type: EXPERIMENTAL): Oral topotecan + IV Bevacizumab

Based on this trial design, predict the completion outcome and termination type (if applicable).